Log In
Print
BCIQ
Print
Print this Print this
 

CV9103

  Manage Alerts
Collapse Summary General Information
Company CureVac GmbH
DescriptionModified single-stranded mRNA vaccine coding for 4 different antigens
Molecular Target Prostate stem cell antigen (PSCA) ; Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC); Treat prostate cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today